Fred Hutch

Study links common immune cell to failure of checkpoint inhibitors in lung cancer

For many lung cancer patients, the best treatment options involve checkpoint inhibitors. These immunotherapy drugs unleash a patient’s immune system against their disease and can yield dramatic ...
Forbes

Another Approach To Checkpoint Inhibitors: Targeting Receptors

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
Forbes

A Deeper Look at Anti-PD-1/PD-L1 Checkpoint Inhibitors for Cancer

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
GEN

Checkpoint Protein Propped Up by Cell-Surface Sidekick

Many cancer cells duck the immune system’s T cells by displaying programmed death-ligand 1 (PD-L1), a cell-surface protein that engages programmed cell death protein 1 (PD-1), another cell-surface ...
Medical Xpress

Study identifies new PD-1 immune checkpoint mechanism promoting Merkel cell carcinoma growth

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating ...
Business Wire

City of Hope Study Finds a Novel Mechanism of Action for Natural Killer Cells in Checkpoint Inhibitor Therapy for Cancer

DUARTE, Calif.--(BUSINESS WIRE)--PD-L1 checkpoint inhibitors are a powerful and growing form of immunotherapy used to treat melanoma, kidney cancer, head and neck cancers, Hodgkin’s lymphoma and other ...